Synthesis of N-aryl and N-arylcarbamoylamino derivatives of 1,3-diazinane-5-carboxamide and their activity against glioblastoma LN-229 cell line.

Bioorg Med Chem

Louisiana State University Health Sciences Center, Department of Pharmacology and Experimental Therapeutics, 1901 Perdido St., New Orleans, LA 70112, United States; Department of Ophthalmology, LSUHSC, New Orleans, United States.

Published: December 2016

Six structural motifs based on the initial (lead) structure of merbarone were designed, prepared, and tested against the glioblastoma LN-229 cell line. Three different structural moieties were modified in the search for optimal glioblastoma activity: the 1,3-diazinane moiety, the aryl moiety, and the heteroatom linker. Calculated molecular descriptors such as lipophilicity (ClogP), acidic strength (calculated pK), and polar surface area (PSA) were used to design a diverse structural library of these compounds. From six different structural motifs and 136 compounds, a handful of examples with moderate (100μg/ml), good (10μg/ml) and excellent (1μg/ml) glioblastoma activity were elucidated.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmc.2016.09.074DOI Listing

Publication Analysis

Top Keywords

glioblastoma ln-229
8
ln-229 cell
8
structural motifs
8
glioblastoma activity
8
synthesis n-aryl
4
n-aryl n-arylcarbamoylamino
4
n-arylcarbamoylamino derivatives
4
derivatives 13-diazinane-5-carboxamide
4
13-diazinane-5-carboxamide activity
4
glioblastoma
4

Similar Publications

Hypoxia is a hallmark of the glioblastoma multiforme microenvironment and represents a promising therapeutic target for cancer treatment. Herein, we report nitroaromatic-based triazene prodrugs designed for selective activation by tumoral endogenous reductases and release of the cytotoxic methyldiazonium ion a self-immolative mechanism. While compounds bearing a 2-nitrofuran bioreductive group were more efficiently activated by nitroreductases, 4-nitrobenzyl prodrugs 1b, 1d and 1e elicited a more pronounced cytotoxic effect against LN-229 and U-87 MG glioblastoma cell lines under hypoxic conditions when compared to temozolomide (TMZ), the golden standard for glioblastoma treatment.

View Article and Find Full Text PDF

Glutaminase controls the first step in glutaminolysis, impacting bioenergetics, biosynthesis and oxidative stress. Two isoenzymes exist in humans, GLS and GLS2. GLS is considered prooncogenic and overexpressed in many tumours, while GLS2 may act as prooncogenic or as a tumour suppressor.

View Article and Find Full Text PDF

Albumin and Polysorbate-80 Coated Sterile Nanosuspensions of Mebendazole for Glioblastoma Therapy.

AAPS PharmSciTech

November 2024

College of Pharmacy and Health Sciences, St. John's University, St. Albert Hall, B-49, 8000 Utopia Parkway, Queens, New York, 11439, USA.

The scarcity of existing and novel therapies for brain cancer has significantly affected the survival rate of glioblastoma patients. Mebendazole (MBZ), an antiparasitic agent demonstrated promising activity against brain cancer. However, poor solubility, multiple polymorphs, and insufficient permeability through blood-brain barrier (BBB) restricts its therapeutic efficacy through parenteral administration.

View Article and Find Full Text PDF

Low-Basicity 5-HT Receptor Ligands from the Group of Cyclic Arylguanidine Derivatives and Their Antiproliferative Activity Evaluation.

Int J Mol Sci

September 2024

Department of Chemical Technology and Environmental Analytics, Faculty of Chemical Engineering and Technology, Cracow University of Technology, 24 Warszawska Street, 31-155 Cracow, Poland.

The serotonin 5-HT receptor (5-HTR), expressed almost exclusively in the brain, affects the Cdk5 signaling as well as the mTOR pathway. Due to the association of 5-HTR signaling with pathways involved in cancer progression, we decided to check the usefulness of 5-HTR ligands in the treatment of CNS tumors. For this purpose, a new group of low-base 5-HTR ligands was developed, belonging to arylsulfonamide derivatives of cyclic arylguanidines.

View Article and Find Full Text PDF

Glioblastoma (GBM), an aggressive primary brain tumor originating from glial cells, poses significant treatment challenges due to its rapid growth and invasiveness. The exact mechanisms of GBM's brain damage remain unclear. This study examines primary molecular markers commonly assessed in GBM patients, including brain-derived neurotrophic factor (BDNF), platelet-derived growth factor receptor A (PDGFRA), O-methylguanine DNA methyltransferase (MGMT), epidermal growth factor receptor (EGFR), and vascular endothelial growth factor A (VEGFA) using computational approaches.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!